Catherine M. Szyman - 03 May 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP, Critical Care
Signature: Linda J. Park, Attorney-in-Fact
Issuer symbol: EW
Transactions as of: 03 May 2024
Net transactions value: -$334,174
Form type: 4
Filing time: 06 May 2024, 19:18:20 UTC
Previous filing: 26 Apr 2024
Next filing: 09 May 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Tax liability	$40,744	-479	-1.1%	$85.06	43,222	03 May 2024	Direct
transaction	EW	Common Stock	Options Exercise	$0	+5,796	+13%	$0.000000	49,018	04 May 2024	Direct	F1
transaction	EW	Common Stock	Tax liability	$293,430	-3,442	-7%	$85.25	45,576	04 May 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Performance Rights	Options Exercise	$0	-5,796	-100%	$0.000000^*	0	04 May 2024	Common Stock	5,796		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

Content

On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.